On April 7, 2017 REGiMMUNE Corporation reported the closing of a Series E financing on April 7th (Press release, REGimmune, APR 7, 2017, View Source [SID1234642231]). The company raised 6 million US in this new round, which was led by SMBC Venture Capital Co., Ltd., the VC arm of Sumitomo Mitsui Banking Corporation(SMBC) and Japan Asia Investment Corporation (JAIC). Additional investors participating in this round are new investors Miyako Capital,Iyo-Gin Capital, Oita Venture Capital, Kyoritsu Captal,Hiroshima Venture Capital and several individual investors. Existing investors, and Mitsubishi UFJ Bank Capital also invested in this financing. Proceeds from this funding will be used clinical　study in US.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

REGiMMUNE successfully completed a Phase I/2a study of RGI-2001 for Graft versus Host Disease (GvHD) . Data from the Phase I/2a study showed no safety concerns up to the highest dose and some preliminary signs of efficacy were observed.

Kenzo Kosuda, President and Chief Executive Officer, said "We now have positive human clinical data that validates the usefulness of our immune-regulating technology platform. The financing announced today will allow us to start an addinotal clinical study to gain the more human data."